Currently, 66% of clinical trials are conducted in North America, Western Europe and Australia.
Currently, 66% of clinical trials are conducted in North America, Western Europe and Australia. The U.S. hosts 49% of clinical trial sites and generates approximately 40% of clinical data. Other regions have arisen in recent years. The main reasons behind this globalization trend are the availability of highly skilled professionals in new research markets, lower costs, faster patient recruitment that allows for earlier drug application approvals and concentrations of huge populations for future drug sales.
Central and Eastern Europe participates in about 13% of clinical trials conducted in Europe and in about 5% of those conducted globally.
However, this number was as high as 7.5% in 2006. In relative terms, the decline here goes as far as 28% over the last six years. It has been observed in all countries of this region, especially Poland, Croatia and the Baltic states.
In this Applied Clinical Trials article, Thomas Novak, Maxim Belotserkovsky, and Ginny Payeur look at whether this surprising finding represents a fluctuation or a new trend.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.